

UVADEX® (methoxsalen) Reference Bibliography

This bibliography contains verifiable peer-reviewed manuscripts and abstracts on the use of Uvadex in Cutaneous T-cell Lymphoma. Human studies, reports and health economic and outcomes analyses (HEOR), are included and, where available, links to PubMed are provided.

Updated: August 2020

Prospective Studies

1. Bisaccia E, Vonderheid EC, Geskin L. Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma. *Br J Dermatol*. 2009;161(1):167-9. [Link](#)
2. Crovetti G, Carabelli A, Berti E, Guizzardi M, Fossati S, De FC, Bertani E. Photopheresis in cutaneous T-cell lymphoma: five-year experience. *Int J Artif Organs*. 2000;23(1):55-62. [Link](#)
3. Duvic M, Chiao N, Talpur R. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. *J Cutan Med Surg*. 2003;7(4 suppl):3-7. [Link](#)
4. Duvic M, Hester J, Lemak N. Photopheresis therapy for cutaneous T-cell lymphoma. *J Am Acad Dermatol*. 1996;35(4):573-9. [Link](#)
5. Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, Vonderheid E, Knobler R, Wolff K, Plewig G. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. *N Engl J Med*. 1987;316(6):297-303. [Link](#)
6. Heald PW, Edelson RL. Photopheresis therapy of cutaneous T cell lymphoma. *Keio J Med*. 1988;37(2):155-167. [Link](#)
7. Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel T, Campbell K, Geskin L. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. *Photodermatol Photoimmunol Photomed*. 2012;28(5):250-7. [Link](#)
8. Knobler R, Foss F, Duvic M, Straus D, Horwitz S, Zain J, Kuzel T, Querfeld C, Campbell K, Geskin L. Efficacy of extracorporeal photopheresis (ECP) monotherapy in the treatment of cutaneous T cell lymphoma (CTCL). *J Invest Dermatol*. 2008;128:S201.
9. Konstantinow A, Balda B-R. Treatment of cutaneous T-cell lymphoma with extracorporeal photochemotherapy. *J Eur Acad Dermatol Venereol*. 1997;9(2):111-117. [Link](#)
10. Nagatani T, Matsuzaki T, Kim S, Baba N, Osawa J, Sugiyama A, Komatsu H, Ichiyama S, Takahashi Y, Miyamoto H, et al. Treatment of cutaneous T-cell lymphomas (CTCL) with extracorporeal photochemotherapy--preliminary report. *J Dermatol*. 1990;17(12):737-45. [Link](#).
11. Ni X, Austin M, Langridge T, Bojaxhi P, Bijani P, Wang X, Duvic M. CD209(+) monocyte-derived myeloid dendritic cells were increased in patients with leukemic cutaneous T-cell lymphoma undergoing extracorporeal photopheresis via the CELLEX^(TM) system. *Photodermatol Photoimmunol Photomed*. 2020;36(4):290-298. [Link](#)
12. Prinz B, Behrens W, Holzle E, Plewig G. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma--the Dusseldorf and Munich experience. *Arch Dermatol Res*. 1995;287(7):621-6. [Link](#)
13. Sanchez SO, Molina LM, Montserrat CM, Bedate OS, Navarro SC, Medina MIG. Extracorporeal photopheresis in sezary syndrome treatment: Hospital-based blood bank experience. *Transfusion*. 2017;57:97A.
14. Siakantaris MP, Tsigiotis P, Stavroyianni N, Argyropoulos KV, Girkas K, Pappa V, Chondropoulos S, Papadavid E, Sakellari I, Anagnostopoulos A, Antoniou C, Dervenoulas J. Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience. *Transfus Apher Sci*. 2012;46(2):189-93. [Link](#)
15. Stevens SR, Baron ED, Masten S, Cooper KD. Circulating CD4+CD7- lymphocyte burden and rapidity of response: Predictors of outcome in the treatment of sezary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis. *Arch Dermatol*. 2002;138(10):1347-1350. [Link](#)
16. Talpur R, Demierre MF, Geskin L, Baron E, Pugliese S, Eubank K, Zic JA, Miller DR, Tharp M, Bohjanen K, Duvic M. Multicenter photopheresis intervention trial in early-stage mycosis fungoides. *Clin Lymphoma Myeloma Leuk*. 2011;11(2):219-27. [Link](#)

17. Wollina U, Liebold K, Kaatz M, Looks A, Stuhler A, Lange D. Survival of patients with cutaneous T-cell lymphoma after treatment with extracorporeal photochemotherapy. *Oncol Rep.* 2000;7(6):1197-201. [Link](#)
18. Wollina U, Looks A, Meyer J, Knopf B, Koch HJ, Liebold K, Hipler UC. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. *J Am Acad Dermatol.* 2001;44(2):253-60. [Link](#)
19. Wollina U, Looks A, Meyer J, Knopf B, Koch HJ, Liebold K, Hipler UC. Treatment of cutaneous T cell lymphoma stage II with interferon-alpha-2a and extracorporeal photochemotherapy: a prospective controlled trial. *Ann N Y Acad Sci.* 2001;941:210-3. [Link](#).
20. Wollina U, Looks A, Lange D, Merkel U, Balogh A. Combined treatment of cutaneous T-cell lymphomas with extracorporeal photopheresis and interferon alpha-2a. *International Journal of Oncology.* 1997;11:887.
21. Ying Z, Shiue L, Park K, Kollet J, Bijani P, Goswami M, Duvic M, Ni X. Blood transcriptional profiling reveals IL-1 and integrin signaling pathways associated with clinical response to extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma. *Oncotarget.* 2019; 10(34):3183-3197 [Link](#)
22. Zic J, Arzubiaga C, Salhany K, Parker R, Wilson D, Stricklin G, Greer J, King LJ. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. *J Am Acad Dermatol.* 1992;27(5 pt 1):729-36. [Link](#)

Retrospective Studies

23. Arulogun S, Prince H, Gambell P, Lade S, Ryan G, Eaton E, McCormack C. Extracorporeal photopheresis for the treatment of Sezary syndrome using a novel treatment protocol. *J Am Acad Dermatol.* 2008;59(4):589-595. [Link](#)
24. Bisaccia E, Gonzalez J, Palangio M, Schwartz J, Klainer AS. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution. *J Am Acad Dermatol.* 2000;43(2 Pt 1):263-271. [Link](#)
25. Booken N, Weiss C, Utikal J, Felcht M, Goerdts S, Klemke C. Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sezary syndrome. *J Dtsch Dermatol Ges.* 2010;8(6):428-438. [Link](#)
26. Duvic M, Hester J, Lemak N. Photopheresis therapy for cutaneous T-cell lymphoma. *J Am Acad Dermatol.* 1996;35(4):573-579. [Link](#)
27. Evans A, Wood B, Scarisbrick J, Fraser-Andrews E, Chinn S, Dean A, Watkins P, Whittaker S, Russell-Jones R. Extracorporeal photopheresis in Sezary syndrome: hematologic parameters as predictors of response. *Blood.* 2001;98(5):1298-301. [Link](#)
28. Gao C, McCormack C, van der Weyden C, Goh MS, Campbell BA, Twigger R, Buelens O, Harrison SJ, Khoo C, Lade S, Prince HM. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sezary syndrome. *Blood.* 2019;134(16):1346-1350. [Link](#)
29. Gottlieb SL, Wolfe JT, Fox FE, DeNardo BJ, Macey WH, Bromley PG, Lessin SR, Rook AH. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. *J Am Acad Dermatol.* 1996;35(6):946-957. [Link](#)
30. Heald P, Rook A, Perez M, Wintroub B, Knobler R, Jegasothy B, Gasparro F, Berger C, Edelson R. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. *J Am Acad Dermatol.* 1992;27(3):427-433. [Link](#)
31. Prinz B, Behrens W, Holzle E, Plewig G. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma--the Dusseldorf and Munich experience. *Arch Dermatol Res.* 1995;287(7):621-626. [Link](#)
32. Sanford KW, Anderson J, Roseff S, McPherson RA. Iron deficiency anemia in patients undergoing extracorporeal photopheresis for cutaneous t-cell lymphoma. *Lab Med.* 2019;50(1):29-33. [Link](#)
33. Seremet S, Abhyankar S, Herd T, Aires D. 75% Complete response and 15% partial response to extracorporeal photopheresis combined with other therapies in resistant early stage cutaneous T-cell lymphoma. *J Drugs Dermatol.* 2016;15(10):1212-1216. [Link](#)

34. Stevens SR, Baron ED, Masten S, Cooper KD. Circulating CD4+CD7- lymphocyte burden and rapidity of response: Predictors of outcome in the treatment of sezary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis. *Arch Dermatol.* 2002;138(10):1347-1350. [Link](#)
35. Wollina U, Liebold K, Kaatz M, Looks A, Stuhler A, Lange D. Survival of patients with cutaneous T cell lymphoma after treatment with extracorporeal photochemotherapy: a retrospective single-center analysis. *Ann N Y Acad Sci.* 2001;941:217-219. [Link](#)
36. Zic J, Stricklin G, Greer J, Kinney M, Shyr Y, Wilson D, King LJ. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. *J Am Acad Dermatol.* 1996;35(6):935-945. [Link](#)

Case Reports

37. Armus S, Keyes B, Cahill C, Berger C, Crater D, Scarborough D, Klainer A, Bisaccia E. Photopheresis for the treatment of cutaneous T cell lymphoma. *J Am Acad Dermatol.* 1990;23(5 pt 1):898-902. [Link](#)
38. Lewis DJ, Duvic M. Extracorporeal photopheresis for the treatment of early-stage mycosis fungoides. *Dermatol Ther.* 2017;30(3):12485. [Link](#).
39. Sanli H, Akay B, Anadolu R, Ozcan M, Saral S, Akyol A. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome. *J Drugs Dermatol.* 2011;10(4):403-408. [Link](#)

Cost Effectiveness Studies

40. Dehle F, Gennari F, Peacock A, Taylor C, Mesa ZO. Cost-effectiveness of extracorporeal photopheresis for the treatment of erythrodermic (stage T4, MO) cutaneous t-cell lymphoma patients in the australian setting [ISPOR abstract PMD8]. *Value Health.* 2020;23(suppl 1):S189
41. Geskin L, Malone DC. An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma. *J Dermatolog Treat.* 2018;29(5):522-530. [Link](#)
42. Geskin L, Hines L, Sharma V, Malone D. Cost-effectiveness analysis of systemic treatments for cutaneous t-cell lymphoma [WCCL abstract J-01]. Abstract presented at 3rd World Congress of Cutaneous Lymphomas 2016, October 26-28, 2016. New York, NY. 2016.
43. Huang X, Li X, Luo L, Shamseddine N, Gao X. Continuation of systemic treatment in patients with cutaneous T-cell lymphoma is associated with reduced health care resource utilization [AAD abstract 10470]. *J Am Acad Dermatol.* 2019;81(4 suppl 1):AB38.
44. Ling Y, Huang X, Mitri G, Pham A, Lovelace B, Knobler R, Gao X. Use of extracorporeal photopheresis (ECP) in the treatment of patients with cutaneous T-cell lymphoma (CTCL), 2010-2015 [ASH abstract 4093]. *Blood.* 2017;130:4093.
45. Ling YL, Huang X, Mitri G, Lovelace B, Pham A, Knobler R, Li X, Gao X. Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010-2015. *J Dermatolog Treat.* 2020;31(1):91-98. [Link](#)
46. Malone D, Hines L, Parenti D, Grossberg H. A cost-effectiveness analysis of treatments for cutaneous t-cell lymphoma [ASA abstract 14]. *J Clin Apher.* 2013;28(2):94-95.

There is a vast body of clinical data in the peer-reviewed literature regarding the therapeutic use of extracorporeal photopheresis. For more information, please contact our Medical Information Group by phone at 800.844.2830, by fax at 913.451.6409, or by email at medinfo@mnk.com